AZD3470

DRUG3 trials

Sponsors

Astrazeneca AB, AstraZeneca

Conditions

Advanced Solid Tumors That Are MTAP DeficientAdvanced/metastatic solid tumors that are MTAP deficient.Hodgkin LymphomaLymphomaNon-Hodgkin

Phase 1

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

RecruitingNCT06130553

AstraZenecaAdvanced Solid Tumors That Are MTAP Deficient

Start: 2024-01-18End: 2026-02-26Target: 234Updated: 2026-03-06

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

RecruitingNCT06137144

AstraZenecaHodgkin Lymphoma, Lymphoma, Non-Hodgkin

Start: 2024-01-23End: 2026-05-08Target: 110Updated: 2025-06-12

PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient

RecruitingCTIS2023-506757-38-00

Astrazeneca ABAdvanced/metastatic solid tumors that are MTAP deficient.

Start: 2024-11-27Target: 40Updated: 2025-09-02

Related Papers

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Blood2024-11-053 citations

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

Blood2024-11-051 citations

PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors.

Journal of Clinical Oncology2024-06-019 citations

Abstract LB008: Integrative dynamic MultiOMICs analysis identifies cell cycle and DNA damage response phenotypes as downstream consequences of using the PRMT5 inhibitor AZD3470

Cancer Research2024-04-053 citations